Mycobacterium Tuberculosis
15
5
6
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.7%
1 terminated out of 15 trials
85.7%
-0.8% vs benchmark
20%
3 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (15)
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment
Shortened Regimen for Drug-susceptible TB in Children
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
The Influence of Malnutrition, Diabetes Mellitus, and Helminth Infections on Biosignatures in Latent Tuberculosis in a South Indian Population
Evaluation of PATHFAST-LAM as a Tuberculosis Treatment Monitoring Tool in Kenya
Diagnosis of Tuberculosis in Swiss Children
Characteristics and Outcomes of TB and HIV Co-infections
New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis
Immune Responses to Mycobacterium Tuberculosis
A Cluster-Randomized Trial of DOTS vs DOTS Plus Active Case Finding
Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
Tuberculosis in a Multiethnic Inner City Population
TB Nutrition, Immunology and Epidemiology
Rapid Characterization of Paucibacillary TB Along Tex/Mex Border